Literature DB >> 31633153

The New Biology of Diabetic Kidney Disease-Mechanisms and Therapeutic Implications.

Yuliya Lytvyn1, Petter Bjornstad2, Daniel H van Raalte3, Hiddo L Heerspink4,5, David Z I Cherney1.   

Abstract

Diabetic kidney disease remains the most common cause of end-stage kidney disease in the world. Despite reductions in incidence rates of myocardial infarction and stroke in people with diabetes over the past 3 decades, the risk of diabetic kidney disease has remained unchanged, and may even be increasing in younger individuals afflicted with this disease. Accordingly, changes in public health policy have to be implemented to address the root causes of diabetic kidney disease, including the rise of obesity and diabetes, in addition to the use of safe and effective pharmacological agents to prevent cardiorenal complications in people with diabetes. The aim of this article is to review the mechanisms of pathogenesis and therapies that are either in clinical practice or that are emerging in clinical development programs for potential use to treat diabetic kidney disease. © Endocrine Society 2019. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 31633153      PMCID： PMC7156849          DOI： 10.1210/endrev/bnz010

Source DB:  PubMed          Journal:  Endocr Rev        ISSN： 0163-769X            Impact factor:   19.871


  275 in total

1.  Satavaptan for the management of ascites in cirrhosis: efficacy and safety across the spectrum of ascites severity.

Authors:  Florence Wong; Hugh Watson; Alexander Gerbes; Hendrik Vilstrup; Salvatore Badalamenti; Mauro Bernardi; Pere Ginès
Journal:  Gut       Date:  2011-08-11       Impact factor: 23.059

2.  Change in albuminuria as a surrogate endpoint in chronic kidney disease - Authors' reply.

Authors:  Hiddo J L Heerspink; Josef Coresh; Ron T Gansevoort; Lesley A Inker
Journal:  Lancet Diabetes Endocrinol       Date:  2019-05       Impact factor: 32.069

3.  Vasopressin contributes to hyperfiltration, albuminuria, and renal hypertrophy in diabetes mellitus: study in vasopressin-deficient Brattleboro rats.

Authors:  P Bardoux; H Martin; M Ahloulay; F Schmitt; N Bouby; M M Trinh-Trang-Tan; L Bankir
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-31       Impact factor: 11.205

4.  A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy.

Authors:  Shigehiro Katayama; Daishiro Yamada; Mikihiro Nakayama; Takashi Yamada; Masafumi Myoishi; Masaharu Kato; Christina Nowack; Peter Kolkhof; Yoshimitsu Yamasaki
Journal:  J Diabetes Complications       Date:  2016-12-14       Impact factor: 2.852

5.  Regulation of Na+/H+ exchanger NHE3 by glucagon-like peptide 1 receptor agonist exendin-4 in renal proximal tubule cells.

Authors:  Luciene R Carraro-Lacroix; Gerhard Malnic; Adriana C C Girardi
Journal:  Am J Physiol Renal Physiol       Date:  2009-09-23

6.  Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.

Authors:  George L Bakris; Rajiv Agarwal; Juliana C Chan; Mark E Cooper; Ron T Gansevoort; Hermann Haller; Giuseppe Remuzzi; Peter Rossing; Roland E Schmieder; Christina Nowack; Peter Kolkhof; Amer Joseph; Alexander Pieper; Nina Kimmeskamp-Kirschbaum; Luis M Ruilope
Journal:  JAMA       Date:  2015-09-01       Impact factor: 56.272

7.  Low-dose vasopressin increases glomerular filtration rate, but impairs renal oxygenation in post-cardiac surgery patients.

Authors:  G Bragadottir; B Redfors; A Nygren; J Sellgren; S-E Ricksten
Journal:  Acta Anaesthesiol Scand       Date:  2009-06-30       Impact factor: 2.105

8.  Haemodynamic and renal effects of endothelin receptor antagonism in patients with chronic kidney disease.

Authors:  Neeraj Dhaun; Charles J Ferro; Anthony P Davenport; William G Haynes; Jane Goddard; David J Webb
Journal:  Nephrol Dial Transplant       Date:  2007-06-07       Impact factor: 5.992

9.  Hyperfiltration, urinary albumin excretion, and ambulatory blood pressure in adolescents with Type 1 diabetes mellitus.

Authors:  Julie A Lovshin; Marko Škrtić; Petter Bjornstad; Rahim Moineddin; Denis Daneman; David Dunger; Heather N Reich; Farid Mahmud; James Scholey; David Z I Cherney; Etienne Sochett
Journal:  Am J Physiol Renal Physiol       Date:  2017-12-13

10.  Endothelial cell and podocyte autophagy synergistically protect from diabetes-induced glomerulosclerosis.

Authors:  Olivia Lenoir; Magali Jasiek; Carole Hénique; Léa Guyonnet; Björn Hartleben; Tillmann Bork; Anna Chipont; Kathleen Flosseau; Imane Bensaada; Alain Schmitt; Jean-Marc Massé; Michèle Souyri; Tobias B Huber; Pierre-Louis Tharaux
Journal:  Autophagy       Date:  2015       Impact factor: 16.016
View more
  16 in total

1.  Liraglutide for the Treatment of Type 2 Diabetes and Safety in Diabetic Kidney Disease: Liraglutide and Diabetic Kidney Disease.

Authors:  David Z Cherney; Katherine R Tuttle
Journal:  Clin J Am Soc Nephrol       Date:  2020-03-04       Impact factor: 8.237

2.  Ertugliflozin and Slope of Chronic eGFR: Prespecified Analyses from the Randomized VERTIS CV Trial.

Authors:  David Z I Cherney; Francesco Cosentino; Samuel Dagogo-Jack; Darren K McGuire; Richard Pratley; Robert Frederich; Mario Maldonado; Chih-Chin Liu; Jie Liu; Annpey Pong; Christopher P Cannon
Journal:  Clin J Am Soc Nephrol       Date:  2021-06-18       Impact factor: 10.614

3.  Sodium-Glucose Cotransporter 2 Inhibitors and the Kidney.

Authors:  Ralph A DeFronzo; Muhammad Abdul-Ghani
Journal:  Diabetes Spectr       Date:  2021-08-18

4.  Effects of Metabolic Factors, Race-Ethnicity, and Sex on the Development of Nephropathy in Adolescents and Young Adults With Type 2 Diabetes: Results From the TODAY Study.

Authors: 
Journal:  Diabetes Care       Date:  2021-09-16       Impact factor: 17.152

5.  Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A Post Hoc Analysis from the CREDENCE Trial.

Authors:  Megumi Oshima; Brendon L Neuen; JingWei Li; Vlado Perkovic; David M Charytan; Dick de Zeeuw; Robert Edwards; Tom Greene; Adeera Levin; Kenneth W Mahaffey; Luca De Nicola; Carol Pollock; Norman Rosenthal; David C Wheeler; Meg J Jardine; Hiddo J L Heerspink
Journal:  J Am Soc Nephrol       Date:  2020-09-30       Impact factor: 10.121

6.  Proximal Tubule mTORC1 Is a Central Player in the Pathophysiology of Diabetic Nephropathy and Its Correction by SGLT2 Inhibitors.

Authors:  Aviram Kogot-Levin; Liad Hinden; Yael Riahi; Tal Israeli; Boaz Tirosh; Erol Cerasi; Ernesto Bernal Mizrachi; Joseph Tam; Ofri Mosenzon; Gil Leibowitz
Journal:  Cell Rep       Date:  2020-07-28       Impact factor: 9.423

Review 7.  Cardiorenal Protection in Diabetic Kidney Disease.

Authors:  Jason F Lee; Ecaterina Berzan; Vikas S Sridhar; Ayodele Odutayo; David Z I Cherney
Journal:  Endocrinol Metab (Seoul)       Date:  2021-04-19

8.  Markers of Kidney Injury, Inflammation, and Fibrosis Associated With Ertugliflozin in Patients With CKD and Diabetes.

Authors:  Hongyan Liu; Vikas S Sridhar; Leif Erik Lovblom; Yuliya Lytvyn; Dylan Burger; Kevin Burns; Davor Brinc; Patrick R Lawler; David Z I Cherney
Journal:  Kidney Int Rep       Date:  2021-06-05

Review 9.  Antioxidant and Anti-inflammatory Properties of Resveratrol in Diabetic Nephropathy: A Systematic Review and Meta-analysis of Animal Studies.

Authors:  Heng-Chang Hu; Yuan-Hong Lei; Wei-Hua Zhang; Xiao-Qiong Luo
Journal:  Front Pharmacol       Date:  2022-03-09       Impact factor: 5.810

10.  Aortic pulse wave velocity, central pulse pressure, augmentation index and chronic kidney disease progression in individuals with type 2 diabetes: a 3- year prospective study.

Authors:  Jian-Jun Liu; Sylvia Liu; Janus Lee; Resham L Gurung; M Yiamunaa; Keven Ang; Yi Ming Shao; Robin W M Choo; Subramaniam Tavintharan; Wern Ee Tang; Chee Fang Sum; Su Chi Lim
Journal:  BMC Nephrol       Date:  2020-08-20       Impact factor: 2.388
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.